biostudies-literatureUnknown38(27)You B<h4>Purpose</h4>Women with gestational trophoblastic tumors (GTT) resistant to single-agent chemotherapy receive alternative chemotherapy regimens, which, although effective, cause considerable toxicity. All GTT subtypes express programmed death-ligand 1 (PD-L1), and natural killer (NK) cells are involved in trophoblast immunosurveillance. Avelumab (anti-PD-L1) induces NK cell-mediated cytotoxicity. The TROPHIMMUN trial assessed avelumab in women with chemotherapy-resistant GTT.<h4>Methods</h4>In this phase II multicenter trial (ClinicalTrials.gov identifier: NCT03135769), women with GTT who experienced disease progression after single-agent chemotherapy received avelumab 10 mg/kg intravenously every 2 weeks until human chorionic gonadotropin (hCG) normalization, followed by 3 consolidatioJournal of clinical oncology : official journal of the American Society of Clinical Oncology3129-3137https://www.ebi.ac.uk/biostudies/studies/S-EPMC7499607biostudies-literatureAvelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial.PMC7499607Roux ALotz JPMassardier JBin SMercier CMaucort-Boulch DGrazziotin-Soares DJoly FHajri TAlves-Ferreira MLanglois-Jacques CBolze PADevouassoux-Shisheboran MGolfier FGladieff LYou BVilleneuve LFreyer GRousset PfalseAvelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial.<h4>Purpose</h4>Women with gestational trophoblastic tumors (GTT) resistant to single-agent chemotherapy receive alternative chemotherapy regimens, which, although effective, cause considerable toxicity. All GTT subtypes express programmed death-ligand 1 (PD-L1), and natural killer (NK) cells are involved in trophoblast immunosurveillance. Avelumab (anti-PD-L1) induces NK cell-mediated cytotoxicity. The TROPHIMMUN trial assessed avelumab in women with chemotherapy-resistant GTT.<h4>Methods</h4>In this phase II multicenter trial (ClinicalTrials.gov identifier: NCT03135769), women with GTT who experienced disease progression after single-agent chemotherapy received avelumab 10 mg/kg intravenously every 2 weeks until human chorionic gonadotropin (hCG) normalization, followed by 3 consolidatio2020-01-01T00:00:00Z2020 Sep2025-04-19T09:43:41.975Z2022-02-11T11:07:57.049ZS-EPMC74996073271674010.1200/JCO.20.00803